Arcellx Inc (ACLX NASDAQ) stock market data APIs
$86.156
1.74(2%)
as of November 7, 2025
Try our APIs with
free plan!
Arcellx Inc Financial Data Overview
Price chart is built with
Anychart
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Prev. Close
86.156
Open
87.8978
High
87.8978
Low
84.6058
52 wk Range
47.8601-107.37
Market Cap
5 100 M
Shares Outstanding
57 823 K
Revenue
35 898 K
EPS
-0.94
Beta
0.313
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Arcellx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Arcellx Inc data using free add-ons & libraries
Get Arcellx Inc Fundamental Data
Arcellx Inc Fundamental data includes:
- Net Revenue: 35 898 K
- EBITDA: -235 908 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -1.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arcellx Inc News
New
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.48 per share a year ago. These figures are ...
Arcellx Provides Third Quarter 2025 Financial Results
REDWOOD CITY, Calif., November 05, 2025--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patie...
Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates
Kura Oncology (KURA) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.63 per share a year ago. These figures are ...
Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition
-- A more recent data cut will be shared during an oral presentation for the iMMagine-1 study -- -- To date, no delayed neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guilla...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
